Stock Track | Mesoblast Soars 11.20% as Quarterly Ryoncil Sales Generate $21.9 Million Revenue

Stock Track

Oct 07, 2025

Mesoblast Ltd (MSB.AU) shares are soaring in Tuesday's trading session, surging by 11.20% following the company's announcement of strong quarterly sales figures for its flagship product, Ryoncil.

The biotechnology company reported gross revenue of $21.9 million for the quarter, attributed to sales of Ryoncil. This impressive financial performance has evidently boosted investor confidence, driving the significant uptick in Mesoblast's stock price.

Ryoncil, Mesoblast's lead product, is a cell therapy used for the treatment of acute graft versus host disease (aGVHD) in children. The robust sales figures suggest growing market acceptance and potentially expanding use of the therapy, which could signal positive long-term prospects for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141904464"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141904464\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141904464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-07 07:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141904464","market":"nz","top_or_hot":-1,"title":"Stock Track | Mesoblast Soars 11.20% as Quarterly Ryoncil Sales Generate $21.9 Million Revenue","media":"Stock Track","content":"<p>Mesoblast Ltd (MSB.AU) shares are soaring in Tuesday's trading session, surging by 11.20% following the company's announcement of strong quarterly sales figures for its flagship product, Ryoncil.</p>\n\n<p>The biotechnology company reported gross revenue of $21.9 million for the quarter, attributed to sales of Ryoncil. This impressive financial performance has evidently boosted investor confidence, driving the significant uptick in Mesoblast's stock price.</p>\n\n<p>Ryoncil, Mesoblast's lead product, is a cell therapy used for the treatment of acute graft versus host disease (aGVHD) in children. The robust sales figures suggest growing market acceptance and potentially expanding use of the therapy, which could signal positive long-term prospects for the company.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mesoblast Soars 11.20% as Quarterly Ryoncil Sales Generate $21.9 Million Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mesoblast Soars 11.20% as Quarterly Ryoncil Sales Generate $21.9 Million Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-07 07:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mesoblast Ltd (MSB.AU) shares are soaring in Tuesday's trading session, surging by 11.20% following the company's announcement of strong quarterly sales figures for its flagship product, Ryoncil.</p>\n\n<p>The biotechnology company reported gross revenue of $21.9 million for the quarter, attributed to sales of Ryoncil. This impressive financial performance has evidently boosted investor confidence, driving the significant uptick in Mesoblast's stock price.</p>\n\n<p>Ryoncil, Mesoblast's lead product, is a cell therapy used for the treatment of acute graft versus host disease (aGVHD) in children. The robust sales figures suggest growing market acceptance and potentially expanding use of the therapy, which could signal positive long-term prospects for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MSB.AU","symbol_name":"MESOBLAST LTD","start_time":0,"source_url":"","article_id":"1141904464","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141904464","pubTimestamp":1759791762,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mesoblast Ltd (MSB.AU) shares are soaring in Tuesday's trading session, surging by 11.20% following the company's announcement of strong quarterly sales figures for its flagship product, Ryoncil....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MSB.AU":"MESOBLAST LTD"},"translate_title":"股票追踪|Mesoblast飙升11.20%Ryoncil季度销售收入2190万美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSB.AU":1},"content_text":"Mesoblast Ltd (MSB.AU) shares are soaring in Tuesday's trading session, surging by 11.20% following the company's announcement of strong quarterly sales figures for its flagship product, Ryoncil.\nThe biotechnology company reported gross revenue of $21.9 million for the quarter, attributed to sales of Ryoncil. This impressive financial performance has evidently boosted investor confidence, driving the significant uptick in Mesoblast's stock price.\nRyoncil, Mesoblast's lead product, is a cell therapy used for the treatment of acute graft versus host disease (aGVHD) in children. The robust sales figures suggest growing market acceptance and potentially expanding use of the therapy, which could signal positive long-term prospects for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}